Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2003
03/25/2003US6537584 Polymer blends that swell in an acidic environment and deswell in a basic environment
03/25/2003US6537583 Method for preparing capsules consisting of a liquid active material core enclosed in a mineral coating
03/25/2003US6537579 Compositions and methods for administration of pharmacologically active compounds
03/25/2003US6537578 Once-a-day controlled release sulfonylurea formulation
03/25/2003US6537576 Biologically active composition
03/25/2003US6537575 Synthetic biological membrane with self organizing properties
03/25/2003US6537573 Combination dosage form comprising cetirizine and pseudoephedrine
03/25/2003US6537556 Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation process
03/25/2003US6537541 Implantation of HSV-TK retrovirus producer cells to destroy glioma
03/25/2003US6537532 Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
03/25/2003US6537524 Inflammatory or obstructive airways disease
03/25/2003US6537519 Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
03/25/2003US6537265 Method for nasal application of a medicinal substance
03/25/2003CA2405202A1 Pharmaceutical composition containing two active ingredients for smoking cessation
03/25/2003CA2243657C Compositions for treatment of erectile dysfunction
03/25/2003CA2234319C Fluoro-substituted adamantane derivatives
03/25/2003CA2177492C Preparation of hollow microcapsules
03/25/2003CA2149052C Dry mix formulation for bisphosphonic acids
03/25/2003CA2107961C Injectable mesna solutions
03/20/2003WO2003022997A2 Human tissue urokinase type plasminogen activator formulation
03/20/2003WO2003022996A2 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
03/20/2003WO2003022995A2 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
03/20/2003WO2003022991A2 Compositions and methods of use of targeting peptides against placenta and adipose tissues
03/20/2003WO2003022910A1 Synthesis and uses of polymer gel nanoparticle networks
03/20/2003WO2003022869A2 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof
03/20/2003WO2003022360A2 Thermotherapy via targeted delivery of nanoscale magnetic particles
03/20/2003WO2003022310A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003WO2003022297A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue
03/20/2003WO2003022292A1 Oral pharmaceutical formulation containing active carbon and use of the same
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022281A1 Improvement of the local compatibility during intravenous administration of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluormethyl-benzoylguanidine
03/20/2003WO2003022279A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines and a tiotropium salt
03/20/2003WO2003022275A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines
03/20/2003WO2003022267A1 Pharmaceutical compositions containing terbinafin and use thereof
03/20/2003WO2003022265A1 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
03/20/2003WO2003022264A1 Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof
03/20/2003WO2003022260A1 Use of methotrexate and l-arginine for the preparation of a medicament for treatment of uterine myoma
03/20/2003WO2003022257A1 External preparations for the skin
03/20/2003WO2003022254A1 Oily thixotropic formulations
03/20/2003WO2003022253A1 Dosage forms having prolonged active ingredient release
03/20/2003WO2003022249A1 New self emulsifying drug delivery system
03/20/2003WO2003022248A1 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
03/20/2003WO2003022247A1 Injectable composition of paclitaxel
03/20/2003WO2003022246A1 Treating effects of excessive reactive oxygen species
03/20/2003WO2003022244A1 Vascular occlusion solid-phase agent with immobilised platelet binding agent
03/20/2003WO2003022243A2 Sustained release of microcrystalline peptide suspensions
03/20/2003WO2003022242A1 Preparation of sustained release pharmaceutical composition
03/20/2003WO2003022239A2 Stable water in oil aminophylline emulsions
03/20/2003WO2003022229A1 Fluid-to-powder compositions
03/20/2003WO2003022218A2 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
03/20/2003WO2003022217A2 Treatment of excessive radiation (e.g. sunburn) exposure
03/20/2003WO2003022210A2 Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
03/20/2003WO2003022208A2 Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
03/20/2003WO2003022192A1 Eustachian tube stent
03/20/2003WO2003022071A2 Colorant for food and pharmaceuticals
03/20/2003WO2003004466A3 Dye-sulfenates for dual phototherapy
03/20/2003WO2002101412A3 Spray freeze-dried compositions
03/20/2003WO2002100319A3 Method for cleaning hard gelatine capsules
03/20/2003WO2002098464A3 Liquid polymer composition for prevention and treatment of the oral cavity diseases
03/20/2003WO2002098226B1 Method for reducing muscle fatigue through administration of adenosine triphosphate
03/20/2003WO2002096496A8 Embolic devices capable of in-situ reinforcement
03/20/2003WO2002096354A3 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002092131A3 Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
03/20/2003WO2002087509A3 Colloidal metal compositions and methods
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002083113A3 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
03/20/2003WO2002076411A3 Dermatological agent for the treatment of skin trauma, especially in burn conditions
03/20/2003WO2002067951A3 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
03/20/2003WO2002049606A3 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv
03/20/2003WO2002028408A3 Compositions and methods for the transport of biologically active agents across cellular barriers
03/20/2003WO2002026262A9 Compositions for reducing side effects in chemotherapeutic treatments
03/20/2003WO2002018620A3 Neutrokine-alpha and neutrokine-alpha splice variant
03/20/2003WO2001090153A3 Reagents for cell selection and methods of use
03/20/2003WO2001085219A3 Identification, diagnosis, and treatment of breast cancer
03/20/2003US20030055307 Devices for detection and therapy of atheromatous plaque
03/20/2003US20030055227 Process for obtaining lignan
03/20/2003US20030055226 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
03/20/2003US20030055211 Anionic polyelectrolyte; may be mixed with other water soluble anionic polyelectrolyte, especially sodium alginate, to form admixtures or blends from which films, fibers, powders, gels sponges can be prepared
03/20/2003US20030055109 Stability
03/20/2003US20030055107 Forms of pharmaceutically active agents and method for manufacture thereof
03/20/2003US20030055102 For therapy of allergic or inflammatory disorders of the eye and nose
03/20/2003US20030055067 For therapy and prophylaxis of fungal infections
03/20/2003US20030055052 FAP-activated anti-tumor compounds
03/20/2003US20030055034 Preparing a concentrated inhalable aztreonam formulation comprising aztreonam dissolved in an aerosolable solution; delivering aztreonam dry powder or the aerosolable solution to the lung endobronchial space of airways of a patient
03/20/2003US20030055028 Administering two separate dosage forms of a topically active corticosteroid or a pharmaceutically active salt thereof for therapy ofinflammatory bowel disease and sufficient to reduce or eliminate side effects
03/20/2003US20030055026 Formoterol/steroid bronchodilating compositions and methods of use thereof
03/20/2003US20030055023 Injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection
03/20/2003US20030055012 Prodrugs of COX-2 inhibitors
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054997 OB protein compositions and methods
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054988 Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
03/20/2003US20030054980 Ceruloplasmin and uses thereof in neurodegenerative related conditions
03/20/2003US20030054979 Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
03/20/2003US20030054977 Covalently linking an antitumor agent to the protonated form of a polyglutamic acid polymer in an inert organic solvent, precipitating the conjugate by adding aqueous salt solution, and collecting the conjugate as protonated solid
03/20/2003US20030054532 Reduction in aggregation of enzymes in liquid solutions; obtain sample containing enzymatic polypeptide, incubate with modulator, monitor adjustment in aggregation activity
03/20/2003US20030054494 Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
03/20/2003US20030054439 Truncated soluble tumor necrosis factor type-I and type-II receptors
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
1 ... 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 ... 1712